Kenai 公司开展iPS来源干细胞治疗帕金森症1期临床研究

在一项大胆的新试验中，医生们正将实验室培育的干细胞植入患者的大脑，以重启帕金森病患者体内多巴胺的生成过程。

In a bold new trial, doctors are implanting lab-grown stem cells into the brain to reboot dopamine production in Parkinson’s disease.

帕金森病是一种长期的神经系统疾病，病情会随着时间的推移而逐渐恶化。

Parkinson's disease is a long term neurological condition that gradually worsens over time.

目前的药物和疗法能够缓解症状，但尚无任何疗法被证实能够阻止或减缓该疾病的进程。

Current medications and therapies can ease symptoms, but no treatment has been proven to stop or slow the disease itself.

这种状况与大脑中多巴胺水平的下降密切相关。

The condition is closely linked to a drop in dopamine levels in the brain.

随着产生多巴胺的脑细胞逐渐死亡，大脑便失去了正常调节运动的能力。

As dopamine producing brain cells progressively die off, the brain loses its ability to properly regulate movement.

南加州大学凯克医学院的研究人员目前正在测试一种新的方法，旨在直接解决这种多巴胺缺失的问题。

Researchers at Keck Medicine of USC are now testing a new approach that aims to address this dopamine loss directly.

在一期临床试验中，医生们将经过特殊改造的干细胞植入大脑中。

In an early phase clinical trial, doctors are implanting specially engineered stem cells into the brain.

这些细胞替换受损的神经元并产生多巴胺。

These cells are designed to replace damaged neurons and generate dopamine.

“如果大脑能够再次分泌出正常水平的多巴胺，那么帕金森病的病情或许就能得到缓解，患者的运动功能也能得以恢复。”凯克医学中心的神经外科医生、该研究的首席研究员布莱恩·李博士说道。

"If the brain can once again produce normal levels of dopamine, Parkinson's disease may be slowed down and motor function restored," said Brian Lee, MD, PhD, a neurosurgeon with Keck Medicine and principal investigator of the study.

这种治疗方法使用的是一种新型的人工合成干细胞，即诱导多能干细胞（iPSCs）。

The treatment uses a newer type of lab created stem cell known as induced pluripotent stem cells (iPSCs).

为了将细胞送达目标位置，李医生在颅骨上开一个小口，以便能够到达大脑。

To deliver the cells, Lee creates a small opening in the skull to reach the brain.

在磁共振成像（MRI）的引导下，他小心翼翼地将干细胞放入基底神经节，该区域负责协调身体动作。

Using magnetic resonance imaging (MRI) for guidance, he carefully places the stem cells into the basal ganglia, the region responsible for coordinating movement.

这项多中心临床试验共涉及 12 名患有中度至重度帕金森病的患者。

The multisite clinical trial includes 12 people with moderate to moderate-severe Parkinson's disease.

这种被称为 RNDP-001 的干细胞疗法是由肯艾生物技术公司研发的，该公司专注于开发治疗神经疾病的方法。

The stem cell therapy, known as RNDP-001, is produced by Kenai Therapeutics, a biotechnology company focused on developing treatments for neurological disorders.

美国食品药品监督管理局已授予其临床试验“REPLACE™ 一期试验”的快速通道认定，这一认定旨在加快试验的开发和审查进程。

The U.S. Food & Drug Administration has granted the clinical trial, Phase 1 REPLACE™, fast-track designation, which is intended to speed up the development and review process.